VITARESC BIOTECH AG
VitaResc Biotech is a biotechnology company engaged in the development of proprietary products that selectively modulate in vivo nitric oxide (NO) levels.
VITARESC BIOTECH AG
Industry:
Biotechnology
Founded:
1999-01-01
Address:
Martinsried, Bayern, Germany
Country:
Germany
Status:
Active
Contact:
+498985652850
Similar Organizations
Vascular Imaging
Vascular Imaging is a biotechnology company engaged in the development of medical devices.
More informations about "VitaResc Biotech AG"
VitaResc Biotech AG - Crunchbase Company Profile & Funding
VitaResc Biotech is a biotechnology company engaged in the development of proprietary products that selectively modulate in vivo nitric oxide (NO) levels.See details»
Evotec OAI and VitaResc Biotech Extend Collaboration in Anti …
VitaResc Biotech AG is a development-stage biotechnology company founded in March 1999 and located in Munich-Martinsried, Germany and Durham, North Carolina, USA. VitaResc is …See details»
Curacyte AG - Crunchbase Company Profile & Funding
Curacyte AG is a bio pharmaceutical company that develops therapeutics for acute and critical care. Where is Curacyte AG's headquarters? Curacyte AG is …See details»
Apex Bioscience Parent to Merge With Fellow German Drug …
Jun 14, 2002 · VitaResc Biotech, which was founded in March 1999 and acquired Apex Bioscience that same year, is a development-stage company focused on novel treatments for …See details»
Curacyte, VitaResc Merging As Part Of German Consolidation
Jun 12, 2002 · MUNICH, Germany - German firms Curacyte AG and VitaResc Biotech AG are merging to form an integrated biopharmaceutical company under the Curacyte name. …See details»
VitaResc Biotech AG acquired by Curacyte AG - Crunchbase
Acquired Organization: VitaResc Biotech AG VitaResc Biotech is a biotechnology company engaged in the development of proprietary products that selectively modulate. Acquiring …See details»
VitaResc Biotech - Products, Competitors, Financials, Employees ...
Developer of pharmaceuticals for the treatment of systemic inflammatory response syndrome (SIRS). The company's products focus on intensive care medicine, target the prevention of …See details»
VitaResc Biotech AG (Merged With Curacyte AG) - VentureRadar
Currently, we have two divisions: the Plant & Microbial Biotechnology Research, and the Biological Production Development Divisions. Our Plant & Microbial Biotechnology Research …See details»
VitaResc Biotech AG - BioCentury Company Profiles - BCIQ
VitaResc Biotech AG - BioCentury Company Profiles for the biopharma industrySee details»
Curacyte Company Profile 2024: Valuation, Funding & Investors
Developer of advanced biopharmaceutics intended to treat acute and critical diseases. The company's advanced biopharmaceutics develops new medicines in the areas of hematology, …See details»
VitaResc Biotech Asset Profile - Preqin
Founded in 1999, based in Germany, VitaResc Biotech is a biotechnology company. It engaged in the development of the products that modulate in vivo nitric oxide (NO) levels.See details»
VitaResc Biotech - CB Insights
See VitaResc Biotech funding rounds, investors, investments, exits and more. Evaluate their financials based on VitaResc Biotech's post-money valuation and revenue.See details»
VitaResc Biotech AG - Crunchbase
VitaResc Biotech is a biotechnology company engaged in the development of proprietary products that selectively modulate.See details»
BioCentury - Breaking the spell in Germany?
Feb 17, 2003 · Indeed, there was only one significant German biotech merger last year, when Curacyte AG merged with fellow Munich company VitaResc Biotech AG to extend its portfolio …See details»
VitaResc Acquisition Of Apex To Fund Septic Shock Treatment …
Jul 12, 1999 · The acquisition of Apex Bioscience by Munich-based start-up VitaResc Biotech AG will provide for the financing of a Phase III program in nitric oxide-induced shock with Apex' …See details»
VitaResc Biotech - CB Insights
Explore {VitaResc Biotech's key management people. Discover current leadership team members including founders, CEO, other executives and board directors.See details»
People - Nature Biotechnology
Ulrich Delvos has been appointed senior vice president, R&D and chief scientific officer at Aventis Behring (King of Prussia, PA). Previously, Dr. Delvos was the founder and CEO of VitaResc...See details»
Curacyte AG - Funding, Financials, Valuation & Investors
Curacyte AG has acquired VitaResc Biotech AG on Jun 10, 2002. Which types of acquisition does this organization make most frequently? Show. Curacyte AG is a bio pharmaceutical company …See details»
Evotec and VitaResc extend VTR-TI deal
Evotec OAI and VitaResc Biotech have extended their collaboration forthe development of the latter's selective synthetic thrombin inhibitor, VTR-TI. Under the terms of the agreement, which …See details»
PHP-HT (VitaResc Biotech) - PubMed
VitaResc (formerly Apex) is developing PHP-HT, pyridoxalated hemoglobin polyoxyethylene conjugate, for the potential treatment of nitric oxide-induced shock (characterized by …See details»